Masimo Corporation (NASDAQ:MASI) Receives $189.40 Consensus Target Price from Analysts

Shares of Masimo Corporation (NASDAQ:MASI) have been given a consensus rating of “Hold” by the eight brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $189.40.

Several equities research analysts have commented on MASI shares. BTIG Research increased their price objective on shares of Masimo from $198.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Bank of America initiated coverage on Masimo in a report on Monday, November 17th. They set a “neutral” rating and a $162.00 price target on the stock. Wells Fargo & Company reissued an “overweight” rating and issued a $190.00 price objective on shares of Masimo in a research report on Friday, December 5th. Wall Street Zen raised Masimo from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Zacks Research cut Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its holdings in shares of Masimo by 44.5% in the 1st quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider’s stock worth $7,311,000 after purchasing an additional 13,513 shares during the period. AQR Capital Management LLC grew its holdings in Masimo by 136.5% during the first quarter. AQR Capital Management LLC now owns 8,142 shares of the medical equipment provider’s stock valued at $1,305,000 after purchasing an additional 4,700 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Masimo by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock worth $1,894,000 after buying an additional 66 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Masimo in the first quarter valued at $220,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Masimo by 1,267.1% during the 1st quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock valued at $367,000 after buying an additional 2,040 shares during the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Trading Down 1.8%

NASDAQ MASI opened at $129.83 on Friday. The company has a current ratio of 2.84, a quick ratio of 1.92 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $139.43 and a 200 day simple moving average of $146.55. Masimo has a 12 month low of $125.94 and a 12 month high of $194.88. The firm has a market capitalization of $6.97 billion, a P/E ratio of -12.32, a PEG ratio of 1.35 and a beta of 1.26.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, November 4th. The medical equipment provider reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.12. Masimo had a negative net margin of 33.20% and a positive return on equity of 33.04%. The firm had revenue of $371.20 million during the quarter, compared to analyst estimates of $366.89 million. During the same quarter in the prior year, the business posted $0.86 EPS. The business’s revenue was up 8.2% compared to the same quarter last year. Masimo has set its FY 2025 guidance at 5.620-5.790 EPS. On average, analysts predict that Masimo will post 4.1 EPS for the current fiscal year.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.